~~<i id='AB0D0DB9E8'><strike id='AB0D0DB9E8'><tt id='AB0D0DB9E8'><pre id='AB0D0DB9E8'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

fashion

author：knowledge 2025-09-08 09:24:53 - browse：7517

Monica Bertagnolli -- health policy coverage from STAT — NIH Director Monica Bertagnolli Kevin Dietsch/Getty Images

WASHINGTON — President Biden has promised to require fair prices from drugmakers that use federally funded research — and now, in a major recent move, said he’ll trigger government “march-in” on patents for drugs that run afoul of that goal.

“It’s a simple principle. You shouldn’t pay the highest price in the world for drugs that your tax dollars have already helped create,” Biden said last month as he touted the move at the National Institutes of Health.

But the new NIH director, locked in the center of this debate, isn’t taking any big steps yet.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Medicare drug price negotiation legal challenge met with skepticism

knowledge

hotspot

focus

Wikipedia

explore

focus

AdobeTherearepeopleinyourlifewhoinfluenceandshapehowyouseetheworld.Forme,oneofthesepeopleisTerryMoak

WSS

Eye stem cell transplant could help restore vision in injured people

Why Medicare shouldn’t cover every FDA

ActiGraph execs on goal of drug approvals with digital endpoints

Trump cancels press conference intended to dispute Georgia election interference charges

Bernie Sanders is gearing up to subpoena pharma CEOs

An interview with Robert F. Kennedy Jr. on vaccines

focus

fashion

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Reconstructing family trees of blood cells may help predict disease

Wildfire smoke exposes gaps in outdoor worker protections

Biogen walks away from Aduhelm, years after polarizing approval

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: CG Oncology IPO, Eli Lilly, Tesla, Merck

At least 13 dead in Texas as scorching temps continue

As Maui death toll rises, number of missing remains unclear

BioMarin wins approval for gene therapy to treat hemophilia A

10 reasons why health care startups fail

hotspot

Bernie Sanders is gearing up to subpoena pharma CEOs

How generative AI ratchets up security threats for health systems

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Beware the threat of staffing cuts at the CDC

Reconstructing family trees of blood cells may help predict disease

Baltimore teen accused of firing into crowd during block party mass shooting

focus

Wikipedia

explore

focus